AM

Anurita Majumdar

Director Director DIN 05291758
DIN 05291758 First appointment May 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2012
Shareholding value •••• Premium profile

About Anurita Majumdar

Data last updated:

Anurita Majumdar was a Director at Eli Lilly And Company (India ) Private Limited (2012–2015) and Whole-Time Director at Pfizer Limited (2016–2019). The companies operate in Pharma.

DIN 05291758
Primary Designation Director
Industry Pharma
First Appointment 03 May 2012

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 May 20121993₹1,004 Cr (FY 2025)Active
Pfizer Limited L24231MH1950PLC008311
Whole-Time Director04 Nov 20161950₹2,454 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Eli Lilly And Company (India ) Private Limited
Pfizer Limited
Premium access

Shareholding and investment profile for Anurita Majumdar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anurita Majumdar

Anurita Majumdar was first appointed on 03 May 2012 as Director at Eli Lilly And Company (India ) Private Limited. The most recent appointment on record is 04 Nov 2016 at Pfizer Limited.

Anurita Majumdar held 2 earlier board appointments: Eli Lilly And Company (India ) Private Limited (Director, 03 May 2012 to 17 Jul 2015); Pfizer Limited (Whole-Time Director, 04 Nov 2016 to 08 Mar 2019).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available